Table 1.
Baseline characteristics of study cohorts and number of deaths from CVD, non-CVD, and all causes in individuals with FPG <6.1 mmol/l and 2-h plasma glucose <7.8 mmol/l
| Countries and studies | n (men/women) | Age (years) | FPG (mmol/l)* | 2-h PG (mmol/l)* | No. of deaths (men/women) |
Follow-up years | ||
|---|---|---|---|---|---|---|---|---|
| CVD | Non-CVD | All cause | ||||||
| Demark | ||||||||
| Glostrup | 461/544 | 54 (39–70) | 5.4 (5.4–5.5) | 5.9 (5.8–5.9) | 98/61 | 68/47 | 166/108 | 17.1 (15.6, 19.1) |
| Finland | ||||||||
| East-West | 187/— | 76 (70–90) | 5.2 (5.1–5.3) | 5.6 (5.5–5.8) | 69/— | 34/— | 103/— | 8.8 (4.6, 14.8) |
| FINRISK 1987 | 985/1,100 | 53 (44–64) | 5.1 (5.1–5.1) | 5.6 (5.5–5.6) | 125/58 | 84/60 | 209/118 | 19.8 (19.8, 19.9) |
| FINRISK 1992 | 566/814 | 54 (44–64) | 5.3 (5.2–5.3) | 5.5 (5.4–5.5) | 28/11 | 16/36 | 44/47 | 14.9 (14.8, 14.9) |
| FINRISK 2002 | 842/1,323 | 57 (45–74) | 5.5 (5.5–5.5) | 5.5 (5.5–5.6) | 5/3 | 9/7 | 14/10 | 4.8 (4.8, 4.9) |
| Helsinki policemen | 687/— | 45 (31–69) | 5.6 (5.5–5.6) | 5.4 (5.3–5.5) | 199/— | 108/— | 307/— | 32.9 (21.8, 36.2) |
| Oulu | 93/172 | 55 (55–55) | 5.4 (5.4–5.5) | 6.1 (5.9–6.2) | 1/2 | 9/6 | 10/8 | 10.0 (10.0, 10.1) |
| Vantaa | 147/188 | 65 (64–66) | 5.3 (5.2–5.3) | 6.2 (6.1–6.3) | 16/6 | 3/3 | 19/9 | 13.3 (13.1, 13.6) |
| Italy | ||||||||
| Cremona Study | 618/794 | 57 (40–88) | 5.0 (5.0–5.0) | 4.9 (4.9–5.0) | 54/47 | 66/42 | 120/89 | 15.1 (14.6, 15.6) |
| Poland | ||||||||
| MONICA | 98/116 | 57 (44–73) | 5.3 (5.2–5.3) | 5.7 (5.5–5.8) | 9/1 | 3/2 | 12/3 | 6.5 (6.4, 6.5) |
| Sweden | ||||||||
| Malmö | —/834 | 54 (48–57) | 5.6 (5.6–5.7) | 6.6 (6.5–6.7) | —/11 | —/31 | —/42 | 14.6 (13.7, 17.8) |
| MONICA | 1,315/1,365 | 46 (25–74) | 5.1 (5.1–5.1) | 5.2 (5.2–5.3) | 31/11 | 22/21 | 53/32 | 12.6 (2.6, 16.6) |
| ULSAM | 651/— | 71 (70–74) | 5.1 (5.1–5.1) | 5.8 (5.7–5.9) | 62/— | 65/— | 127/— | 10.2 (9.1, 11.1) |
| The Netherlands | ||||||||
| Hoorn Study | 798/975 | 61 (49–77) | 5.3 (5.2–5.3) | 5.0 (4.9–5.0) | 41/19 | 41/31 | 82/50 | 8.9 (8.3, 9.3) |
| Zutphen Study | 289/— | 76 (70–90) | 5.3 (5.2–5.3) | 5.1 (5.0–5.7) | 29/— | 13/— | 42/— | 4.7 (4.6, 4.8) |
| U.K. | ||||||||
| ELY | 262/411 | 53 (40–67) | 5.5 (5.5–5.5) | 5.6 (5.5–5.7) | 11/3 | 13/17 | 24/20 | 14.6 (13.9, 15.4) |
| Goodinge Study | 214/346 | 52 (39–76) | 5.7 (5.6–5.7) | 5.5 (5.4–5.6) | 10/7 | 7/14 | 17/21 | 8.7 (8.4, 9.0) |
| Newcastle Heart Project | 224/254 | 53 (30–76) | 5.5 (5.5–5.5) | 5.5 (5.4–5.6) | 13/2 | 11/12 | 24/14 | 8.9 (8.5, 9.3) |
| Whitehall II study | 4,129/1,638 | 49 (39–62) | 5.1 (5.1–5.2) | 5.2 (5.2–5.3) | 26/4 | 39/22 | 65/26 | 5.9 (5.6, 6.1) |
| Total | 12,566/10,874 | 54 (25–90) | 5.3 (5.2–5.3) | 5.4 (5.4–5.4) | 827/246 | 611/351 | 1,438/597 | 9.0 (5.8, 14.9) |
Data are n, mean (range), or median (25th, 75th percentiles) unless otherwise indicated.
*Age-adjusted means (95% CIs). MONICA, Monitoring of Trends and Determinants in Cardiovascular Disease; PG, plasma glucose; ULSAM, Uppsala Longitudinal Study of Adult Men.